Champions Oncology, Inc. — Form 10-Q Summary
Reporting period: Three months ended July 31, 2011, the first quarter of the company’s fiscal year ending April 30, 2012. Comparatives are for the three months ended July 31, 2010, unless otherwise noted. The company develops oncology services using its Tumorgraft Technology Platform, serving Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS) customers.
Financial performance
| Metric | Q1 2011 | Q1 2010 |
|---|---|---|
| Revenue | $1.634 million | $1.600 million |
| Gross profit | $732,000 | $1.054 million |
| Gross margin | 44.8% | 65.9% |
| Operating loss | $2.214 million | $603,000 |
| Net loss | $2.037 million | $591,000 |
| Net loss per share, basic and diluted | $0.04 | $0.02 |
| Operating cash used | $1.535 million | $436,000 |
- POS revenue fell 45.8% to $601,000; POS gross margin declined to 20% from 71%. Management attributed the revenue decline and margin pressure to lower pricing as the company re-engineered products for lower price points; higher volumes had not yet offset the price reductions.
- TOS revenue rose 110.4% to $1.033 million, primarily from more contracts and increased sales efforts. TOS gross margin improved to 59% from 55%.
- Operating expenses rose 74.7% to $3.848 million. Sales and marketing increased to $688,000, and general and administrative expense rose to $1.717 million; management cited expanded sales staffing, marketing, personnel growth, and higher share-based compensation. R&D declined 41.1% to $541,000.
- Stock-based compensation was $1.014 million versus $170,000 a year earlier, including $916,000 in general and administrative expense.
Financial position and liquidity
- At July 31, 2011, cash and cash equivalents were $8.839 million, down from $10.457 million at April 30. Working capital was $7.1 million. Management stated cash on hand was adequate to fund operations for at least the next twelve months.
- Operating activities used $1.535 million; investing activities used $95,000, mainly for equipment; financing activities provided $4,000. Cash declined by $1.618 million during the quarter.
- Total assets were $11.801 million. Current liabilities were $3.839 million, including $2.077 million of deferred revenue. The balance sheet reports no conventional debt; the filing states there was no off-balance-sheet debt or similar obligation.
- Stockholders’ equity was a $992,000 deficit. Separately, $8.159 million was classified as redeemable common stock related to the April 2011 financing and its contingent put option.
Outlook, risks and unusual items
- In April 2011, the company raised $9.4 million through a private placement of 12,533,333 common shares at $0.75 per share and issued warrants. Investors may require redemption of their shares for cash at $0.75 per share upon a change of control or sale of substantially all assets, subject to specified termination conditions. Warrants have exercise-price reset provisions and are recorded as a liability; their fair-value decrease generated $177,000 of non-cash income in the quarter.
- The filing describes potential registration-default penalties of $41,000 for each 30-day period. The company said payment was not probable and recorded no accrual. Management cautioned that future capital, if needed, might not be available on acceptable terms and could involve dilution, debt, or restrictive terms.
- Under its Cephalon agreement, the company received a $1.390 million initiation fee in April, recorded as deferred revenue. No revenue was recognized in this quarter because no models had been delivered; the company expected deliveries to begin in its fiscal second quarter. The agreement includes potential milestone payments totaling $27 million and possible royalties, subject to conditions.
- The company had not received approximately $500,000 of an awarded federal grant for qualifying fiscal 2011 expenditures. The filing does not provide a clear expected receipt date beyond saying it was expected during the fiscal year.
- The company licensed Irinophore C and could owe up to $3 million in development milestones, plus royalties and sales milestones if commercialized. A minimum annual royalty of C$10,000 begins in March 2013.
- Management reported no material changes to risk factors previously disclosed in the 2011 Form 10-K. It reported no material litigation exposure, and no material changes to internal control over financial reporting; disclosure controls were assessed as effective.
Important facts for investors to verify
- Whether lower POS pricing results in sustained volume growth and improved margins, and whether TOS contract growth continues.
- Cash consumption, the assumptions behind management’s stated twelve-month funding runway, and the status of the outstanding grant receivable.
- Cephalon study delivery timing and the conditions for recognizing deferred revenue and earning contingent milestones or royalties.
- The terms and potential cash impact of the redeemable-share put option, warrant resets, and registration-default penalties.
- The magnitude and timing of share-based compensation and other spending increases relative to revenue growth.